IMDX:NASDAQ, Insight Molecular Diagnostics Inc.

IMDX stock overview

Insight Molecular Diagnostics Inc. (IMDX:NASDAQ) closed at $2.83 on October 23, 2026, down 0.35% on the day. The stock trades 66.7% below its 52-week high of $8.51 and 16.9% above its 52-week low of $2.42. Over the past year, it lost 57.3%. Insight Molecular Diagnostics Inc. is part of the Health Care sector.

Key figures

Price
$2.83
Day change
-0.35%
Volume
42,478
Average volume
244,687
Market cap
92M+
52-week range
$2.42 – $8.51
50-day average
$3.76
200-day average
$4.86

Price action over the past year

In 252 trading sessions since October 23, 2025, IMDX closed higher on 119 days (47%). Its best day was March 31, 2026 (+28.63%) and its worst was March 30, 2026 (-28.37%). The stock moved 10% or more in a single session 24 times. It opened at least 5% above the previous day's high 1 time.

Recent signals

IMDX news

About Insight Molecular Diagnostics Inc.

Insight Molecular Diagnostics Inc., or iMDx (formerly Oncocyte Corporation), is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. Investors may visit https://investors.imdxinc.com/ for more information.

Similar stocks

Find more stocks like IMDX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.